©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1157-1163
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1157
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1157
Effect of oncometabolic surgery on gastric cancer: The remission of hypertension, type 2 diabetes mellitus, and beyond
Yu-Xi Cheng, Dong Peng, Wei Tao, Wei Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Author contributions: Cheng YX and Peng D contributed equally to this work; Zhang Wei conducted quality evaluation; Peng D and Cheng YX conducted data extraction; Tao Wei conducted figure painting; Cheng YX wrote the manuscript; Peng D, Cheng YX, Tao W and Zhang W conducted writing review and editing; all authors read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Corresponding author: Wei Zhang, PhD, Surgeon, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. cyzhangwei@hotmail.com
Received: May 27, 2021
Peer-review started: May 27, 2021
First decision: June 16, 2021
Revised: June 24, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: September 15, 2021
Processing time: 106 Days and 3.5 Hours
Peer-review started: May 27, 2021
First decision: June 16, 2021
Revised: June 24, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: September 15, 2021
Processing time: 106 Days and 3.5 Hours
Core Tip
Core Tip: The purpose of this review is to discuss the effects of oncometabolic surgery observed in current studies, mainly including the remission of hypertension and type 2 diabetes mellitus after gastrectomy in gastric cancer (GC) patients, and to evaluate the possibility of the remission of other metabolic comorbidities in GC patients who undergo oncometabolic surgery.